Olaratumab failure in sarcomas: what are the lessons learned?

Maud Toulmonde, Carine Bellera, Simone Mathoulin-Pelissier, Marc Debled, Binh Bui, Antoine Italiano, Quality of Randomized Controlled Trials Reporting in the Treatment of Sarcomas Journal of Clinical Oncology. ,vol. 29, pp. 1204- 1209 ,(2011) , 10.1200/JCO.2010.30.9369

Joyce O'Shaughnessy, Cynthia Osborne, John E. Pippen, Mark Yoffe, Debra Patt, Christine Rocha, Ingrid Chou Koo, Barry M. Sherman, Charles Bradley, Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer The New England Journal of Medicine. ,vol. 364, pp. 205- 214 ,(2011) , 10.1056/NEJMOA1011418

William D Tap, Robin L Jones, Brian A Van Tine, Bartosz Chmielowski, Anthony D Elias, Douglas Adkins, Mark Agulnik, Matthew M Cooney, Michael B Livingston, Gregory Pennock, Meera R Hameed, Gaurav D Shah, Amy Qin, Ashwin Shahir, Damien M Cronier, Robert Ilaria, Ilaria Conti, Jan Cosaert, Gary K Schwartz, Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial The Lancet. ,vol. 388, pp. 488- 497 ,(2016) , 10.1016/S0140-6736(16)30587-6

Diego Teyssonneau, Antoine Italiano, Olaratumab for soft tissue sarcoma. Expert Opinion on Biological Therapy. ,vol. 17, pp. 1019- 1025 ,(2017) , 10.1080/14712598.2017.1339031

Caitlin D. Lowery, Wayne Blosser, Michele Dowless, Shelby Knoche, Jennifer Stephens, Huiling Li, David Surguladze, Nick Loizos, Debra Luffer-Atlas, Gerard J. Oakley, Qianxu Guo, Seema Iyer, Brian P. Rubin, Louis Stancato, Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α. Clinical Cancer Research. ,vol. 24, pp. 847- 857 ,(2017) , 10.1158/1078-0432.CCR-17-1258

Georgios Antoniou, Alexander T.J. Lee, Paul H. Huang, Robin L. Jones, Olaratumab in soft tissue sarcoma - Current status and future perspectives. European Journal of Cancer. ,vol. 92, pp. 33- 39 ,(2018) , 10.1016/J.EJCA.2017.12.026

William D Tap, Andrew J Wagner, Zsuzsanna Papai, Kristen N Ganjoo, Chueh-Chuan Yen, Patrick Schoffski, Albiruni Ryan Abdul Razak, Javier Martin Broto, Alexander I Spira, Akira Kawai, Anders Krarup-Hansen, Axel Le Cesne, Brian Van Tine, Yoichi Naito, Se Hoon Park, Victoria Soldatenkova, Gary Mo, Ashwin Shahir, Jennifer Wright, Robin Lewis Jones, None, ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). Journal of Clinical Oncology. ,vol. 37, ,(2019) , 10.1200/JCO.2019.37.18_SUPPL.LBA3